Search Results - jong+ho+chun

2 Results Sort By:
M4N and Temozolomide Combination Therapy for Glioblastoma multiforme (GBM)
Unmet NeedGlioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and remains one of the most aggressive types of malignancies. The mainstay of GBM treatment is surgery, radiation and adjuvant chemotherapy using temozolomide (TMZ). While treatment options have incrementally improved, survival rates remains dismal. Only...
Published: 5/9/2024   |   Inventor(s): Ru Chih Huang, Jong ho Chun, Yu-Ling Lin, Yu-Chuan Liang, Kuang-Wen Liao, Tiffany Jackson, David Mold, Chien-Hsien Lai
Keywords(s): Agonists/Promoters, Brain Cancer, Cancers, Chemotherapy/Immunotherapy, Combination, Disease Indication, Glioblastoma, Glioma, Non-novel, Off-the-shelf, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Oncology > Brain Cancer
Compositions Comprising NDGA Derivatives and Sorafenib and their Use in the Treatment of Cancer
INVENTION NOVELTYJHU investigators have combined the NDGA derivatives M4N and sorafenib to create a pharmaceutical composition that inhibits cancer cell growth. This novel drug combination has increased cytotoxic activity and inhibits growth of HCC human cancer cells in a dose-dependent manner.VALUE PROPOSITIONInvestigators have discovered a drug composition...
Published: 5/9/2024   |   Inventor(s): Jong ho Chun, David Mold, Christopher Ruland, Yu-Chuan Liang, Ru Chih Huang
Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Novel, Predicted Novelty, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type
Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities
2017 - 2022 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum